ANDA 76172, held by Actavis Labs Fl Inc. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 76172 (Metformin Hydrochloride), held by Actavis Labs Fl Inc, was first approved by FDA on Jun 16, 2004, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 16, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 30Labeling · Standard review | Approved | None posted |
| Feb 26, 2019 | Supplement 25Labeling · Standard review | Approved | None posted |
| Feb 26, 2019 | Supplement 27Labeling · Standard review | Approved | None posted |
| Oct 31, 2008 | Supplement 13Labeling | Approved | None posted |
| May 25, 2007 | Supplement 6Labeling | Approved | None posted |
| Jun 16, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters